Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
J05AB16
|
| gptkbp:brand |
gptkb:remdesivir
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to remdesivir |
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:form |
solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Veklury (COVID-19)
|
| gptkbp:indication |
hospitalized COVID-19 patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
RNA polymerase inhibitor
|
| gptkbp:pregnancyCategory |
not established
|
| gptkbp:sideEffect |
nausea
elevated liver enzymes allergic reactions |
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:WHOStatus |
recommended for certain COVID-19 patients
|
| gptkbp:bfsParent |
gptkb:Gilead
|
| gptkbp:bfsLayer |
5
|